Abstract

The aberrant gain of DNA methylation at CpG islands is frequently observed in colorectal tumours and may silence the expression of tumour suppressors such as MLH1. Current models propose that these CpG islands are targeted by de novo DNA methyltransferases in a sequence-specific manner, but this has not been tested. Using ectopically integrated CpG islands, here we find that aberrantly methylated CpG islands are subject to low levels of de novo DNA methylation activity in colorectal cancer cells. By delineating DNA methyltransferase targets, we find that instead de novo DNA methylation activity is targeted primarily to CpG islands marked by the histone modification H3K36me3, a mark associated with transcriptional elongation. These H3K36me3 marked CpG islands are heavily methylated in colorectal tumours and the normal colon suggesting that de novo DNA methyltransferase activity at CpG islands in colorectal cancer is focused on similar targets to normal tissues and not greatly remodelled by tumourigenesis.

Aberrant gain of DNA methylation at CpG islands is frequently observed in colorectal tumours. Here the authors use ectopically integrated CpG islands in colorectal cancer cells and find that aberrantly methylated CpG islands are subject to low levels of de novo DNA methylation, and that instead de novo DNA methylation activity is targeted primarily to CpG islands marked by the histone modification H3K36me3.

Details

Title
De novo DNA methyltransferase activity in colorectal cancer is directed towards H3K36me3 marked CpG islands
Author
Masalmeh Roza H Ali 1 ; Taglini Francesca 2 ; Rubio-Ramon, Cristina 2 ; Musialik, Kamila I 2 ; Higham, Jonathan 1 ; Davidson-Smith, Hazel 1 ; Kafetzopoulos Ioannis 2   VIAFID ORCID Logo  ; Pawlicka, Kamila P 2 ; Finan, Hannah M 2 ; Clark, Richard 3   VIAFID ORCID Logo  ; Wills Jimi 4 ; Finch, Andrew J 5 ; Murphy, Lee 3   VIAFID ORCID Logo  ; Sproul Duncan 2   VIAFID ORCID Logo 

 University of Edinburgh, MRC Human Genetics Unit, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 University of Edinburgh, MRC Human Genetics Unit, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Edinburgh, CRUK Edinburgh Centre, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 University of Edinburgh, Edinburgh Clinical Research Facility, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 University of Edinburgh, CRUK Edinburgh Centre, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 University of Edinburgh, CRUK Edinburgh Centre, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Queen Mary University of London, Centre for Tumour Biology, Barts Cancer Institute, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2483414217
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.